Clarivate Analytics is a global leader in providing trusted insights and analytics to accelerate the pace of innovation. Our vision is to improve the way the world creates, protects and advances innovation.

Get the insights you need on COVID-19.

Access the world’s leading research and late-breaking news on this rapidly evolving health emergency.

A global health emergency can occur without warning, as we are now seeing with the coronavirus pandemic. Scientists are attempting to develop vaccines and treatments as quickly as possible to meet the increasing needs of those affected. To support medical researchers and healthcare professionals in their efforts to better understand and combat the disease associated with the novel COVID-19 coronavirus, we’ve assembled an array of Clarivate resources on this page.

Check back often for additional content and updates – materials are continually added and/or refreshed.

Review drug targets under investigation.

In this Drugs of the Future article, the Clarivate team reviews targets that are currently under active investigation (as of March 20, 2020) for the treatment of COVID-19, the disease caused by SARS-CoV-2 infection.

Discover the research published on the Coronavirus (COVID-19) from the Web of Science.

The recent emergence of a novel coronavirus (2019‐nCoV), which is causing an outbreak of unusual viral pneumonia in patients in Wuhan, a central city in China, is another warning of the risk of coronaviruses posed to public health. In this mini‐review, we provide a brief introduction of the general features of coronaviruses and describe diseases caused by different coronaviruses in humans and animals. This review will help understand the biology and potential risk of coronaviruses that exist in richness in wildlife such as bats. This article is protected by copyright. All rights reserved.

The current outbreak of viral pneumonia in the city of Wuhan, China, was caused bya novel coronavirus designated 2019‐nCoV by the World Health Organization, asdetermined by sequencing the viral RNA genome. Many initial patients were ex-posed to wildlife animals at the Huanan seafood wholesale market, where poultry,snake, bats, and other farm animals were also sold. To investigate possible virusreservoir, we have carried out comprehensive sequence analysis and comparison inconjunction with relative synonymous codon usage (RSCU) bias among differentanimal species based on the 2019‐nCoV sequence. Results obtained from our ana-lyses suggest that the 2019‐nCoV may appear to be a recombinant virus betweenthe bat coronavirus and an origin‐unknown coronavirus. The recombination mayoccurred within the viral spike glycoprotein, which recognizes a cell surface re-ceptor. Additionally, our findings suggest that 2019‐nCoV has most similar geneticinformation with bat coronovirus and most similar codon usage bias with snake.Taken together, our results suggest that homologous recombination may occur andcontribute to the 2019‐nCoV cross‐species transmission.

A Novel Coronavirus from Patients with Pneumonia in China, 2019

In December 2019, a cluster of patients with pneumonia of unknown cause was linked to a seafood wholesale market in Wuhan, China. A previously unknown betacoronavirus was discovered through the use of unbiased sequencing in samples from patients with pneumonia. Human airway epithelial cells were used to isolate a novel coronavirus, named 2019-nCoV, which formed a clade within the subgenus sarbecovirus, Orthocoronavirinae subfamily. Different from both MERS-CoV and SARS-CoV, 2019-nCoV is the seventh member of the family of coronaviruses that infect humans. Enhanced surveillance and further investigation are ongoing. (Funded by the National Key Research and Development Program of China and the National Major Project for Control and Prevention of Infectious Disease in China.)

Outbreak of Pneumonia of Unknown Etiology in Wuhan China: the Mystery and the Miracle

Summary: Since December 2019, a total of 41 cases of pneumonia of unknown etiology have been confirmed in Wuhan city, Hubei Province, China. Wuhan city is a major transportation hub with a population of more than 11 million people. Most of the patients visited a local fish and wild animal market last month. At a national press conference held today, Dr. Jianguo Xu, an academician of the Chinese Academy of Engineering, who led a scientific team announced that a new‐type coronavirus, tentatively named by World Health Organization as the 2019‐new coronavirus (2019‐nCoV), had caused this outbreak (1).

Recent advances in the detection of respiratory virus infection in humans

Respiratory tract viral infection caused by viruses or bacteria is one of the most common diseases in human worldwide, while those caused by emerging viruses, such as the novel coronavirus, 2019‐nCoV that caused the pneumonia outbreak in Wuhan, China most recently, have posed great threats to global public health. Identification of the causative viral pathogens of respiratory tract viral infections is important to select an appropriate treatment, save people’s lives, stop the epidemics, and avoid unnecessary use of antibiotics. Conventional diagnostic tests, such as the assays for rapid detection of antiviral antibodies or viral antigens, are widely used in many clinical laboratories.

With the development of modern technologies, new diagnostic strategies, including multiplex nucleic acid amplification and microarray‐based assays, are emerging. This review summarizes currently available and novel emerging diagnostic methods for the detection of common respiratory viruses, such as influenza virus, human respiratory syncytial virus (RSV), coronavirus, human adenovirus (hAdV), and human rhinovirus (hRV). Multiplex assays for simultaneous detection of multiple respiratory viruses are also described. It is anticipated that such data will assist researchers and clinicians to develop appropriate diagnostic strategies for timely and effective detection of respiratory virus infections.

The city of Wuhan in China is the focus of global attention due to an outbreak of a febrile respiratory illness due to a coronavirus 2019-nCoV. In December 2019, there was an outbreak of pneumonia of unknown cause in Wuhan, Hubei province in China, with an epidemiological link to the Huanan Seafood Wholesale Market where there was also sale of live animals. Notification of the WHO on 31 Dec 2019 by the Chinese Health Authorities has prompted health authorities in Hong Kong, Macau, and Taiwan to step up border surveillance, and generated concern and fears that it could mark the emergence of a novel and serious threat to public health (WHO, 2020a; Parr, 2020).

The Cortellis Regulatory Intelligence team is closely monitoring the fast-moving landscape, providing updates on guidance from the FDA and other global health authorities. Read these summaries for recent updates:

Bioinfogate, which provides the OFF-X translational safety intelligence portal, has produced a free report that summarizes safety and toxicity alerts related to recent publications and previously-compiled content.

Stay on top of all the latest COVID-19 news with complimentary access to curated BioWorld articles. Coverage includes breaking research, clinical, regulatory and business development news – 600+ articles published to date. The collection also reaches back to 1991.

Topics include: vaccines and diagnostics in development, the science underpinning the virus, comparison to previous outbreaks such as Severe Acute Respiratory Syndrome (SARS) and Middle Eastern respiratory syndrome coronavirus (MERS-CoV), global regulatory factors and the business news underpinning the research including development collaborations and investment trends.

To help share the latest available COVID-19 information, our editorial team is prioritizing all journals in the evaluation pipeline that have a scope relevant to COVID-19 research, including those in public, environmental and occupational health; infectious diseases; virology and immunology.

The Cortellis suite of life science intelligence solutions is cloud-based, which means each can be used remotely from any computer.You have uninterrupted access to the insights you need while working from home.